CRISPR Medicine

Capstan Therapeutics

Company Type: Therapeutic development

Main focus: Developing treatments for various diseases through engineering immune cells and targeting pathogenic cells with mRNA-encoded gene-editing technology

Company stage: Pre-clinical

Diseases: Cancer, autoimmune disorders, fibrosis, and monogenic blood disorders

Genome-editing tool: mRNA-encoded gene editing machinery

Funding stage: Series B

Location: San Diego, California, USA

Website: https://www.capstantx.com/

Pipeline:

Partners:


Capstan Therapeutics is a biotechnology company dedicated to advancing new therapies through targeted and precise in vivo gene- and cell engineering. Their approach to disease treatments follows two distinct pathways; engineering immune cells and targeting pathogenic cells through in vivo gene editing. Capstan’s core technology revolves around targeted lipid nanoparticles (tLNPs) carrying disease-specific payloads.

See the full view ...